



HAL
open science

Specific detection of memory T-cells in COVID-19 patients using standardized whole-blood Interferon gammarelease assay. Letter to the editor

William Mouton, Christelle Compagnon, Kahina Saker, Soizic Daniel, Sophia Djelabi, Xavier Lacoux, Bruno Pozzetto, Guy Oriol, Daphné Laubreton, Margaux Prieux, et al.

► To cite this version:

William Mouton, Christelle Compagnon, Kahina Saker, Soizic Daniel, Sophia Djelabi, et al.. Specific detection of memory T-cells in COVID-19 patients using standardized whole-blood Interferon gammarelease assay. Letter to the editor. *European Journal of Immunology*, 2021, 4p. 10.1002/eji.202149296 . hal-03363725

HAL Id: hal-03363725

<https://hal.science/hal-03363725>

Submitted on 4 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Letter to the Editor

[DOI: 10.1002/eji.202149296]

Specific detection of memory T-cells in COVID-19 patients using standardized whole-blood Interferon gammarelease assay

As our understanding of the immune response against SARS-CoV-2 improves, it becomes clear that virus-specific T-cells are key players in the control of infection and that suboptimal T-cells response contribute to Covid-19 severity in many individuals [1]. SARS-CoV-2 specific T-cell responses often target epitopes conserved in different virus clades, including variants of concern [2], and even in other seasonal human coronaviruses (HCoV) [3,4]. Thus, memory T-cells may be more cross-protective than antibodies against different coronavirus infections. In addition, specific SARS-CoV-2 T-cell responses have been detected in convalescent donors without antibody responses suggesting that, at least in some individuals, the measurement of T-cell responses, mainly investigated using ELISpot assay and/or intracellular cytokine staining (ICS) [3,4], may complement serological measurements to uncover and characterize past infections. Thus, novel immunodiagnos- tics, more suitable for clinical routine than

the two methods mentioned above and measuring cellular immune response to SARS-CoV-2, are needed to assess individual immune status and evaluate emerging vaccines in a robust and standardized manner. For this purpose, we designed a semi-automated whole-blood Interferon gamma release assay (WB IGRA) to detect and quantify SARS-CoV-2-specific T-cells immunity. WB assays are rapid and simple assays that preserve all interactions between circulating immune cells reflecting the, *in vivo*, situation. IFN- γ secretion measurement following stimulation with SARS-CoV-2 peptides was used to reveal SARS-CoV-2 specific T-cell response, notably in whole blood and Peripheral blood mononuclear cells (PBMC) assays as previously reported [5–8]. We monitored T-cell immunity directed against different SARS-CoV-2 proteins including nucleocapsid (N), membrane glycoprotein (M) and the spike receptor-binding domain (RBD) in a cohort of 129 Covid-19 convalescent healthcare workers (HCWs) infected 6 months before with SARS-CoV-2. We correlated these measurements with serological levels of antibodies (Abs) against SARS-CoV-2. We also assessed the specificity of the WB IGRA for SARS-CoV-2 by performing measurements in 25 SARS-CoV-2 seronegative healthy volunteers (HVs) and in three HCWs with previously documented infection by HCoV.

We constituted a cohort of HCWs previously infected by SARS-CoV-2 ($n = 129$) or HCoV ($n = 3$) at 6-month post-symptom period. Among patients, 20 of 129 (16%) SARS-CoV-2 positive HCWs were male (sex ratio, 0.18), the median age was 41 years (21–62 years); one of three (33%) HKU-1 ($n = 1$)/NL-63 ($n = 2$) positive HCWs were male (sex ratio, 0.5) with a median age of 22 years (21–23 years).

We also included HVs ($n = 25$) of which 13 of 25 (52%) were male (sex ratio, 1.08) with a median age of 42 years (19–68 years). We first monitored SARS-CoV-2 specific Abs using the Wantai total Ab kit in the three different groups of participants. These Abs were undetectable in the sera from the three HCoV positive HCWs and from the 25 HVs, confirming the absence of previous SARS-CoV-2 infection. In contrast, they were detected in all 129 HCWs with documented SARS-CoV-2 infection 6 months before. These sera were further characterized, 82.9% ($n = 107$) had IgG against the SARS-CoV-2 RBD domain (bioMérieux VIDAS®) [8–10] and only 48.8% ($n = 63$) scored positive in a virus neutralization test (VNT) (Table 1), confirming previous findings regarding the relative short half-life of neutralizing antibodies (nAbs) in subjects with mild disease [11,12].

We then monitored the T-cell response against M, RBD, and N peptides using the WB IGRA for the different groups. A detectable IFN- γ release was observed for 89.1%, 62.4%, and 97.9% of SARS-CoV-2 positive HCWs (detailed in Table 1) after stimulation with M (Figure 1A), RBD (Figure 1B), and N (Figure 1C) SARS-CoV-2 peptides, respectively. These data suggest that a detectable T-cell response after SARS-CoV-2 peptide stimulation can be observed at 6 months post symptoms, in accordance with recent results [8], and extending previous findings by *Murugesan et al.* [7] who used a similar approach, with different peptides pools, in recently-SARS-CoV-2-infected patients. No or very low IFN- γ release (<0.12 IU/mL) was detected for HVs and HCoV upon stimulation with M (Figure 1A) or RBD (Figure 1B). Interestingly, two of the three HCoV positive HCWs (Mean 0.45

Correspondence: Sophie Trouiller-Assant
e-mail: Sophie.assant@chu-lyon.fr

Table 1. Association of SARS-CoV-2 humoral and cellular response

Assay type	Anti-SARS-CoV-2-RBD	Virus neutralization test
	IgG titer	
Assay type	ELFA	/
Positive, n (%)	107 (82.9)	63 (48.8)
Negative, n (%)	22 (17.1)	66 (51.2)
Overall, Negative and Positive Percent Agreement with WB IGRA M; T-cell responders 115/129 (89.1%) (IFN-γ titer: median 0.51 [0.24-1.49] IU/mL)		
OPA [95%CI]	78.3 [70.4-84.5]	56.6 [48.0-64.8]
PPA [95%CI]	90.7 [83.7-94.8]	96.8 [89.1-99.1]
NPA [95%CI]	18.2 [7.3-38.5]	18.2 [10.7-29.1]
Overall, Negative and Positive Percent Agreement with WB IGRA RBD; T-cell responders 58/93 (62.4%) (IFN-γ titer: median 0.12 [0.17-0.34] IU/mL)		
OPA [95%CI]	71.0 [61.1-79.2]	62.4 [52.2-71.5]
PPA [95%CI]	69.6 [58.8-78.7]	72.6 [59.1-82.9]
NPA [95%CI]	78.6 [52.4-92.4]	50.0 [35.5-64.5]
Overall, Negative and Positive Percent Agreement with WB IGRA N; T-cell responders 92/94 (97.9%) (IFN-γ titer: median 1.20 [0.60-2.48] IU/mL)		
OPA [95%CI]	81.9 [72.9-88.4]	51.1 [41.1-60.9]
PPA [95%CI]	97.5 [91.2-99.3]	100 [92.3-100]
NPA [95%CI]	0 [0-20.4]	4.2 [1.2-14.0]

[0.10-0.79] IU/mL), as well as 44% ($n = 11/25$, Mean 0.20 [0.13-0.32] IU/mL) of the HVs showed a low detectable IFN- γ response upon stimulation with N (Figure 1C). These data suggest that N peptides are able to elicit not only SARS-CoV-2 specific T-cells but also cross-reactive HCoV-specific T-cells, which reinforces the existence of potential pre-existing immunity in HVs, as previously noted [4,13,14,15].

The overall percent agreement between the T-cell responses against

N, M, or RBD WB IGRA and positive anti-SARS-CoV-2-RBD IgG (bioMérieux IgG assay) was of 81.9%, 78.3%, and 71.0%, respectively. Among the 22 COVID-19 convalescent HCWs with undetectable anti-SARS-CoV-2-RBD IgG, only 4 did not have M-specific T-cells, which resulted in a low negative percent agreement (NPA) between cellular and humoral responses (18.2%), interestingly this NPA was null concerning N-specific T-cells i.e. all patients with undetectable anti-SARS-CoV-2-RBD IgG have detectable N-specific

T-cells (detailed in Table 1). Moreover, among the convalescent HCWs who lacked neutralizing Abs at 6 months post-infection, 81.8% ($n = 54/66$) and 95.8% ($n = 46/48$) had M- and N-specific T-cells, respectively. These results highlight that the T-cell response persists longer than neutralizing antibodies, suggesting that the measurement of T-cell responses is important to define the history of past infections.

Finally, we assessed the production of IFN- γ by CD4⁺ T-cells measured by




Figure 1. IFN- γ release after in vitro WB stimulation using SARS-CoV-2 peptide pools. IFN- γ levels measurement in WB of samples from SARS-CoV-2 convalescent HCWs (dot), three HCoV convalescent HCWs (square) and 25 controls (HV) (triangle). IFN- γ secretion was measured on VIDAS automated platform (VIDAS® IFN γ RUO, bioMérieux) after a 22-h stimulation using (A) M peptides, (B) RBD peptides, and (C) N peptides. The median and individual secretion levels are shown. (D) Percentage of IFN- γ positive CD4⁺ T-cells measured by intracellular cytokine staining (ICS) following stimulation of PBMCs from a subset of patients (dot, $n = 60$) and new controls (HV) (triangle, $n = 6$) with a pool of peptides (PepTivator, Miltenyi Biotec) derived from Spike, N, and M proteins as detailed in the methods. Statistical differences were inferred using non-parametric Kruskal-Wallis test and Dunn's multiple comparisons test (A-C) or Mann-Whitney test (D) (*** $p < 0.001$).

intracellular cytokine staining (ICS) following stimulation of PBMCs from a subset of patients ($n = 60$), with a pool of peptides (PepTivator, Miltenyi Biotec) derived from Spike, N, and M proteins (Figure 1D). We observed a 5.3-fold increase of CD4⁺IFN γ ⁺ in SARS-CoV-2 convalescent HCWs compared to HV ($p < 0.001$), suggesting that IFN- γ is mainly produced by SARS-CoV-2 specific CD4⁺ T-cells and confirming the use of IFN- γ release as a relevant marker of T-cell immune response as previously described [5–7].

However, we acknowledge that our study has some limitations: (i) the WB IGRA was not able to differentiate between CD8⁺ and CD4⁺ T-cells responses, (ii) it does not determine whether memory T-cells are protective against SARS-CoV-2 re-infection, (iii) it was not evaluated in vaccinated subjects, and (iv) it is necessary to assess whole Spike protein epitopes including other non-RBD spike epitopes in order to improve detection of vaccine-induced memory T-cells. Nevertheless, a validated [semi-]automatized SARS-CoV-2 WB IGRA would be of interest to assess T-cell memory induced by natural infection or vaccination in the clinical routine.

Here, we present a WB IGRA that is highly efficient in detecting SARS-CoV-2 specific T-cell responses, confirming the reliability of such tests [5–7]. Our results highlight that peptides derived from distinct viral proteins show a different capacity to trigger a T-cell response in patients having recovered from SARS-CoV-2 infection. Stimulation with RBD-peptides was less efficient in inducing IFN- γ secretion than stimulation with M and N peptides in convalescent patients, however this assay could be helpful to assess T-cell memory after SARS-CoV-2 vaccination targeting the Spike RBD domain. Indeed, the induction of protective immune responses composed of Spike or RBD-directed nAbs associated with Th1-type cellular responses, is recommended by WHO. N- and M-peptides both induced the production of high levels of IFN- γ , the stimulation by N could even induce low levels of IFN- γ secretion by HCoV-convalescent HCWs and HVs T-cells indicating that the pool of N-peptides contains

some cross reactive epitopes able to stimulate HCoV induced T-cells. Hence, stimulation with M appears to be more specific and could be used to measure T-cell memory after SARS-CoV-2 natural infection. Alternatively, N peptides located in regions that are conserved between HCoV and SARS-CoV-2 could be removed from the N pool of peptides [3,4] or a higher positivity threshold, more suitable than detection threshold defined by method protocol, could be set using the pool described in this study.

In summary, WB IGRA could thus be proposed as a suitable and rapid option for assessing the presence of a long-term specific T-cell response against SARS-CoV-2.

William Mouton^{1,2,3} ,
Christelle Compagnon^{1,3}, Kahina Saker¹,
Soizic Daniel⁴, Sophia Djebali²,
Xavier Lacoux⁴, Bruno Pozzetto^{5,6},
Guy Oriol^{1,3}, Daphné Laubret²,
Margaux Prieux², Jean-Baptiste Fassier^{7,8},
Nicolas Guibert^{7,8},
Amélie Massardier-Pilonchéry^{7,8},
Dulce Alfaiate^{7,8}, Franck Berthier⁴,
Thierry Walzer² , Jacqueline Marvel²,
Karen Brengel-Pesce^{#1,3}
and Sophie Trouiller-Assant^{#1,2}

¹ Joint Research Unit Hospices Civils de Lyon-bioMérieux, Civils Hospices de Lyon, Pierre-Bénite, Lyon Sud Hospital, Lyon, France

² CIRI- International Centre for Research in Infectiology (CIRI), INSERM U1111, CNRS UMR5308, ENS de Lyon, Claude Bernard Lyon 1 University, Lyon, France

³ Open Innovation & Partnerships (OIP), bioMérieux S.A., Marcy l'Etoile, France

⁴ R&D – Immunoassay, bioMérieux S.A., Marcy l'Etoile, France

⁵ GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), Lyon University, Jean Monnet University, Saint-Etienne, France

⁶ Laboratoire des Agents Infectieux et Hygiène, Saint-Etienne University hospital, Saint-Etienne, France

⁷ Lyon University, Ifsttar, UMRESTTE, UMR T_9405, Claude Bernard Lyon 1 University, Lyon, France

⁸ Occupational Health and Medicine Department, Civils Hospices of Lyon, Lyon, France

[#]These authors share senior authorship.

Acknowledgments: This work was supported by bioMérieux SA that provided kits for this study. This research is being supported by Hospices Civils de Lyon

and by Fondation des Hospices Civils de Lyon (HCL). We thank all the personnel of the occupational health and medicine department of HCL who contributed to the samples collection. We thank Karima Brahami and all members of the clinical research and innovation department for their reactivity (DRCI, HCL). A special thanks to Virginie Pitiot and PMO team for their help in patient enrolment and clinical data collection. Additional funding from the “project IDEXLYON” of Lyon University as part of the “programme d’investissement d’Avenir” (ANR-18-IDEX-0005). We acknowledge the contribution of SFR Biosciences (UAR3444/CNRS, US8/Inserm, ENS de Lyon, UCBL) AnIRACytometry facility.

Conflict of Interest: W.M., C.C., S.Da., X.L., G.O., F.B., and K.B.P are employed in bioMérieux SA, an in vitro diagnostic company. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Peer review: The peer review history for this article is available at <https://publons.com/publon/10.1002/eji.202149296>

1 Sette, A. and Crotty, S., *Cell*. 2021. 184: 861.

2 Skelly, D. T. et al., *In Review*. 2021: <https://www.researchsquare.com/article/rs-226857/v1>

3 Nelde, A. et al., *Nat Immunol*. 2021. 22: 74.

4 Le Bert, N., et al., *Nature*. 2020. 584: 457.

5 Le Bert, N. et al., *J. Exp. Med*. 2021. 218: e20202617.

6 Petrone, L. et al., *Clin. Microbiol. Infect*. 2021. 27: 286.e7–286.e13.

- 7 Murugesan, K. et al., *Clin. Infect. Dis.* 2020. ciaa1537.
- 8 Vallejo, A. et al., *Eur J Clin Invest.* 2021: <https://onlinelibrary.wiley.com/doi/10.1111/eci.13636>
- 9 Dan, J. M. et al., *Science.* 2021. 371: eabf4063.
- 10 Jiang, X. - L. et al., *Nat Commun.* 2021. 12: 897.
- 11 Gaebler, C. et al., *Nature.* 2021. 591: 639.
- 12 Bal, A. et al., *Clin Microbiol Infect.* 2021. 27: 933–935.
- 13 Lau, E. H. Y. et al., *Nat Commun.* 2021. 12: 63.
- 14 Braun, J. et al., *Nature.* 2020. 587: 270.
- 15 Mateus, J. et al., *Science.* 2020. 370: 89.

Abbreviations: **Abs:** antibodies · **HVs:** healthy volunteers · **HCoV** : seasonal human coronaviruses · **HCWs:** healthcare workers · **ICS:** intracytoplasmic staining · **IGRA:** IFN gamma release assay · **IU:** international unit · **M:** membrane glycoprotein · **nAbs:** neutralizing antibodies · **N:** nucleocapsid · **RBD:** receptor-binding domain · **WB:** Whole-blood

Keywords: immune memory · interferon gamma release assay · SARS-CoV-2 · T-cells response

Full correspondence: Sophie Trouillet-Assant, Laboratoire Commun de Recherche Hospices

Civils de Lyon-bioMérieux. Centre Hospitalier Lyon Sud, Bâtiment 3F, Pierre-Bénite, 69495, France. Email: Sophie.assant@chu-lyon.fr

Received: 9/4/2021

Revised: 30/6/2021

Accepted: 4/8/2021

Accepted article online: 13/8/2021



Additional supporting information may be found online in the Supporting Information section at the end of the article.